keyword
https://read.qxmd.com/read/38641354/recent-developments-in-on-demand-voiding-therapies
#21
JOURNAL ARTICLE
Karl B Thor, Lesley Marson, Mary A Katofiasc, Daniel J Ricca, Edward C Burgard
One cannot survive without regularly urinating and defecating. People with neurological injury (spinal cord injury, traumatic brain injury, stroke) or disease (multiple sclerosis, Parkinson's disease, spina bifida) and many elderly are unable to voluntarily initiate voiding. The great majority of them require bladder catheters to void urine and "manual bowel programs" with digital rectal stimulation and manual extraction to void stool. Catheter-associated urinary tract infections frequently require hospitalization, while manual bowel programs are time-consuming (1-2 hours), stigmatizing, and cause rectal pain and discomfort...
April 19, 2024: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/38641336/clinico-radiologic-spectrum-and-outcome-of-paediatric-acquired-demyelinating-disorders-ads-of-central-nervous-system-a-retrospective-indian-tertiary-care-hospital-cohort
#22
JOURNAL ARTICLE
Prithviraj R Prithviraj, Bidisha Banerjee, Ullas V Acharya, Muhammed Hafis, Sruthi K Sasidharan
UNLABELLED: Paediatric acquired demyelinating syndrome(ADS) constitute group of treatable disorders with acute neurologic dysfunction. Neuroimaging has played significant role in diagnosis of ADS. We describe clinico-radiologic spectrum, outcome and compare the groups Acute disseminated encephalomyelitis (ADEM), Neuromyelitis-optica-spectrum disorder (NMOSD), clinically-isolated-syndrome (CIS), Multiple sclerosis (MS) and Myelin-oligodendrocyte-glycoprotein antibody associated disorders (MOGAD)...
April 19, 2024: Neuropediatrics
https://read.qxmd.com/read/38641243/tumor-or-demyelination-three-tumefactive-multiple-sclerosis-case-reports-and-literature-review
#23
REVIEW
Feiteng Qi, Yong Zhang, Xiang Li, Jie Fan, Haibo Tan, Chao Quan
OBJECTIVE: To investigate the clinical diagnosis and treatment of tumefactive multiple sclerosis (TMS). METHODS: Clinical data, laboratory and imaging examinations, and treatment of three patients with TMS were retrospectively analyzed. Data were further analyzed in relation to the literature. RESULTS: All three patients had acute or subacute onset with large lesions on imaging, which were difficult to differentiate from tumors. Two cases had relapses on follow-up and one case had a stereotactic biopsy...
April 17, 2024: World Neurosurgery
https://read.qxmd.com/read/38640586/switching-from-natalizumab-to-an-anti-cd20-monoclonal-antibody-in-relapsing-remitting-multiple-sclerosis-a-systematic-review
#24
JOURNAL ARTICLE
Justin D Brown, Benjamin T Muston, Jennifer Massey
BACKGROUND: Use of natalizumab (NTZ) is precluded in many Multiple Sclerosis (MS) patients by the risk of progressive multifocal leukoencephalopathy (PML). Regardless, some patients may commence natalizumab for short term disease control in spite of being seropositive, and others may seroconvert whilst on treatment. In these circumstances, discontinuation of NTZ should not occur until a clear exit strategy is established to prevent post-NTZ disease reactivation, which often exceeds the severity of disease activity prior to NTZ treatment...
April 18, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38640585/health-related-quality-of-life-and-utilities-among-lebanese-patients-with-multiple-sclerosis-a-cross-sectional-study
#25
JOURNAL ARTICLE
Jalal Dahham, Mickaël Hiligsmann, Ingrid Kremer, Samia J Khoury, Hala Darwish, Hassan Hosseini, Souheil Hallit, Silvia Evers, Rana Rizk
OBJECTIVE: This study assessed the Health-Related Quality of Life (HRQoL) and utilities of Multiple Sclerosis (MS) patients in Lebanon using generic and MS-specific QoL instruments, categorized by disease severity, and explored factors associated with HRQoL. METHODS: This was a cross-sectional, retrospective HRQoL study collecting data through face-to-face interviews using the EQ-5D-5 L and the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaires...
April 16, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38639785/the-role-of-annexins-in-central-nervous-system-development-and-disease
#26
REVIEW
Zachary B White, Sindhu Nair, Markus Bredel
Annexins, a group of Ca2+ -dependent phospholipid-binding proteins, exert diverse roles in neuronal development, normal central nervous system (CNS) functioning, neurological disorders, and CNS tumors. This paper reviews the roles of individual annexins (A1-A13) in these contexts. Annexins possess unique structural and functional features, such as Ca2+ -dependent binding to phospholipids, participating in membrane organization, and modulating cell signaling. They are implicated in various CNS processes, including endocytosis, exocytosis, and stabilization of plasma membranes...
April 19, 2024: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://read.qxmd.com/read/38638671/a-review-of-bruton-s-tyrosine-kinase-inhibitors-in-multiple-sclerosis
#27
REVIEW
Laura Airas, Robert A Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J Williams, Bernd C Kieseier, Heinz Wiendl
Bruton's tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of MS pathogenesis, along with mast cells, establishing the relevance of BTK inhibitors to diverse autoimmune conditions. First-generation BTK inhibitors are currently utilized in the treatment of B-cell malignancies and show efficacy in B-cell modulation. B-cell depleting therapies have shown success as disease-modifying treatments (DMTs) in MS, highlighting the potential of BTK inhibitors for this indication; however, first-generation BTK inhibitors exhibit a challenging safety profile that is unsuitable for chronic use, as required for MS DMTs...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38638559/the-effect-of-multiple-sclerosis-therapy-on-gut-microbiota-dysbiosis-a-longitudinal-prospective-study
#28
JOURNAL ARTICLE
Andreea-Cristina Paraschiv, Vitalie Vacaras, Cristina Nistor, Cristiana Vacaras, Stefan Strilciuc, Dafin F Muresanu
Gut microbiota has complex immune functions, related to different pathologies, including multiple sclerosis (MS).This study evaluated the influence of treatments on gut microbiota in people with MS (PwMS). The research comprised 60 participants, including 39 PwMS and 21 healthy controls (HC). Among the PwMS, 20 were prescribed a disease-modifying therapy (DMT), either interferon beta1a or teriflunomide, while 19 received a combination of classical DMT and an immunoglobulin Y (IgY) supplement. For each participant, two sets of gut samples were collected: one at the study's outset and another after two months...
2024: Microbial Cell
https://read.qxmd.com/read/38638312/prospective-observational-study-to-evaluate-treatment-satisfaction-and-effectiveness-in-patients-with-relapsing-multiple-sclerosis-starting-cladribine-tablets-cladreal-in-italy
#29
JOURNAL ARTICLE
Massimo Filippi, Laura Ferrè, Chiara Zanetta, Caterina Rizzi, Gabriella Pessina, Francesco Assogna, Maria A Rocca
Disease-modifying therapies (DMTs) for multiple sclerosis (MS) reduce relapse frequency, magnetic resonance imaging (MRI) activity, and slow disability progression. Numerous DMTs are approved for relapsing forms of MS although real-world data on patient-reported outcomes (PROs) and quality of life (QoL) are needed to inform treatment choice. Immune reconstitution therapy with cladribine tablets is a highly effective treatment for relapsing MS (RMS). We present the protocol for an observational study to prospectively assess the effectiveness of cladribine tablets on clinical and MRI parameters as well as on PROs, including treatment satisfaction, QoL, sleep quality, self-perceived health, fatigue, and physical function...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38638273/assessing-illness-related-uncertainty-in-relapsing-remitting-multiple-sclerosis-a-psychometric-analysis-of-the-mishel-uncertainty-of-illness-scale
#30
JOURNAL ARTICLE
Julia Sabin, Elisa Salas, Jesús Martín-Martínez, Antonio Candeliere-Merlicco, Francisco Javier Barrero, Ana Alonso, José Luis Sánchez-Menoyo, Laura Borrega, María Rodríguez-Rodríguez, Montserrat Gómez-Gutiérrez, Sara Eichau, Miguel Ángel Hernández-Pérez, Carmen Calles, Eva Fernández-Díaz, Olga Carmona, Aida Orvíz, Ana López-Real, Pablo López-Muñoz, Amelia Mendoza, Eduardo Agüera, Jorge Maurino, Javier Ballesteros
A multicenter study involving 204 adults with relapsing-remitting multiple sclerosis (RRMS) assessed the dimensionality and item characteristics of the Mishel-Uncertainty of Illness Scale (MUIS), a generic self-assessment tool. Mokken analysis identified two dimensions in the MUIS with an appropriate item and overall scale scalability after excluding nonclassifiable items. A refined 12-item MUIS, employing a grade response model, effectively discriminated uncertainty levels among RRMS patients (likelihood ratio test p -value = ...
2024: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://read.qxmd.com/read/38638271/robotic-systems-for-upper-limb-rehabilitation-in-multiple-sclerosis-a-swot-analysis-and-the-synergies-with-virtual-and-augmented-environments
#31
REVIEW
Giulia A Albanese, Anna Bucchieri, Jessica Podda, Andrea Tacchino, Stefano Buccelli, Elena De Momi, Matteo Laffranchi, Kailynn Mannella, Michael W R Holmes, Jacopo Zenzeri, Lorenzo De Michieli, Giampaolo Brichetto, Giacinto Barresi
The robotics discipline is exploring precise and versatile solutions for upper-limb rehabilitation in Multiple Sclerosis (MS). People with MS can greatly benefit from robotic systems to help combat the complexities of this disease, which can impair the ability to perform activities of daily living (ADLs). In order to present the potential and the limitations of smart mechatronic devices in the mentioned clinical domain, this review is structured to propose a concise SWOT (Strengths, Weaknesses, Opportunities, and Threats) Analysis of robotic rehabilitation in MS...
2024: Frontiers in Robotics and AI
https://read.qxmd.com/read/38638247/comparison-of-macular-changes-according-to-the-etiology-of-optic-neuritis-a-cross-sectional-study
#32
JOURNAL ARTICLE
Yeji Moon, Sung-Min Kim, Jae Ho Jung
AIM: To compare the macular structure including foveal thickness among patients with optic neuritis (ON) according to the etiology and to investigate the possible correlation between structural and visual outcomes. METHODS: In this retrospective cross-sectional study, the clinical data of patients with aquaporin-4 immunoglobulin G-related ON (AQP4 group, 40 eyes), myelin oligodendrocyte glycoprotein IgG-related ON (MOG group, 31 eyes), and multiple sclerosis-related ON (MS group, 24 eyes) were obtained...
2024: International Journal of Ophthalmology
https://read.qxmd.com/read/38638121/causal-associations-between-autoimmune-diseases-and-sarcopenia-related-traits-a-bi-directional-mendelian-randomization-study
#33
JOURNAL ARTICLE
Chunlan Chen, Ying He
BACKGROUND: Sarcopenia is common in patients with autoimmune diseases (ADs); however, the causal associations between ADs and sarcopenia remain unclear. Therefore, this study investigated the causal associations using bi-directional Mendelian randomization analysis. METHODS: Exposure-related single-nucleotide polymorphisms (SNPs) were extracted from genome-wide association studies (GWASs). GWAS statistics for common ADs [Crohn's disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis (PSO), and multiple sclerosis (MS)] and sarcopenia-related traits [hand grip strength (HGS), appendicular fat-free mass (FFM), and walking pace] were obtained from public datasets...
2024: Frontiers in Genetics
https://read.qxmd.com/read/38638039/peptide-drugs-current-status-and-treatment-for-the-treatment-of-various-diseases
#34
JOURNAL ARTICLE
Chandani Chandarana, Isha Juwarwala, Shravi Shetty, Anushree Bose
Peptides represent a class of natural molecules with diverse physiological functions, including hormone regulation, neurotransmission, and immune modulation. In recent years, peptide-based therapeutics have gained significant attention in pharmaceutical research and development due to their high specificity, efficacy, and relatively low toxicity. This review provides an overview of the current landscape of peptide drug development, highlighting the challenges faced in their formulation and delivery and the innovative strategies employed to overcome these hurdles...
April 17, 2024: Current Drug Research Reviews
https://read.qxmd.com/read/38638017/programmed-cell-death-in-autoimmune-diseases-ferroptosis
#35
JOURNAL ARTICLE
Jiantao Sun, Lujuan Huang, Jiawei Wang, Yelang Hu, Wenmin Wang, Haihong Zhu
Ferroptosis is an iron dependent cell death driven by lipid peroxidation. Over the past decade, increasing evidence has confirmed that ferroptosis plays an irreplaceable role in the occurrence and development of many diseases, including various cancers, neurodegenerative diseases, cardiovascular diseases and autoimmune diseases. Autoimmune disease is an inflammatory disease characterized by the breakdown of immune tolerance. Nowadays, accumulating evidence indicates that ferroptosis is closely related to the pathogenesis of autoimmune diseases...
April 19, 2024: Annales de Biologie Clinique
https://read.qxmd.com/read/38636270/diet-and-omega-3-and-vitamin-d-supplement-use-predict-five-year-fatigue-and-disability-trajectories-in-people-with-multiple-sclerosis
#36
JOURNAL ARTICLE
Xin Lin, Amin Zarghami, George A Jelinek, Steve Simpson-Yap, Sandra Neate, Nupur Nag
BACKGROUND: Fatigue and disability are indicators of disease progression experienced by many people with multiple sclerosis (pwMS). Understanding trajectories of these outcomes, and their predictors, may provide insight to potential interventions for MS management. METHODS: Survey data from 839 pwMS from the Health Outcomes and Lifestyle in pwMS study were analysed. Fatigue was defined as mean Fatigue Severity Scale >5, and severe disability as Patient Determined Disease Steps >5...
April 8, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38636269/rituximab-induced-gut-microbiota-changes-in-chinese-neuromyelitis-optica-spectrum-disorders
#37
JOURNAL ARTICLE
Hao Chen, Zubing Xu, Yu Zhou, Yu-Huan Jiang, Jin Chen, Yingqiong Xiong, Meihong Zhou, Xiaomu Wu, Daojun Hong
BACKGROUND: Recent evidence shows that immunosuppressive agents can affect the gut microbiota in autoimmune diseases. However, the relationship between the gut microbiome and B-cell depletion immunotherapy in neuromyelitis optica spectrum disorder (NMOSD) remains poorly understood. OBJECTIVES: To evaluate the distinct intestinal microbial patterns and serum cytokine levels after short-term rituximab treatment (three months) in patients with NMOSD. METHODS: Firstly, we conducted a cross-sectional study involving 46 treatment-naïve NMOSD patients and 48 matched healthy controls...
April 16, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38636242/frequency-of-an-intrathecal-igm-synthesis-and-mrz-reaction-in-children-with-ms
#38
JOURNAL ARTICLE
S Chen, Bertolini A, G Koukou, E M Wendel, C Thiels, M Baumann, C Lechner, A Blaschek, A Della Marina, G Classen, B Stüve, B Kauffmann, T Kapanci, B Mayer, M Otto, K Rostásy
BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the CNS. An intrathecal IgM synthesis is associated with a more rapid progression of MS and the intrathecal immune response to measles -, rubella -and varicella zoster virus (MRZR) which, if present, increases the likelihood of a diagnosis of MS in adults. OBJECTIVE: To evaluate the frequency of an intrathecal IgM synthesis and MRZR in children with MS. MethodsChildren with MS and a data set including clinical and treatment history, MRI at onset, in addition to a CSF analysis, and determination of antibody index (AI) of measles, rubella, and zoster antibodies, were eligible...
April 16, 2024: European Journal of Paediatric Neurology: EJPN
https://read.qxmd.com/read/38635941/vulnerability-of-thalamic-nuclei-at-csf-interface-during-the-entire-course-of-multiple-sclerosis
#39
JOURNAL ARTICLE
Ismail Koubiyr, Takayuki Yamamoto, Simon Blyau, Reda A Kamroui, Boris Mansencal, Vincent Planche, Laurent Petit, Manojkumar Saranathan, Romain Casey, Aurélie Ruet, Bruno Brochet, José V Manjón, Vincent Dousset, Pierrick Coupé, Thomas Tourdias
BACKGROUND AND OBJECTIVES: Thalamic atrophy can be used as a proxy for neurodegeneration in multiple sclerosis (MS). Some data point toward thalamic nuclei that could be affected more than others. However, the dynamic of their changes during MS evolution and the mechanisms driving their differential alterations are still uncertain. METHODS: We paired a large cohort of 1,123 patients with MS with the same number of healthy controls, all scanned with conventional 3D-T1 MRI...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38635657/generation-and-characterization-of-monoclonal-antibodies-against-pathologically-phosphorylated-tdp-43
#40
JOURNAL ARTICLE
Paula Castellanos Otero, Tiffany W Todd, Wei Shao, Caroline J Jones, Kexin Huang, Lillian M Daughrity, Mei Yue, Udit Sheth, Tania F Gendron, Mercedes Prudencio, Björn Oskarsson, Dennis W Dickson, Leonard Petrucelli, Yong-Jie Zhang
Inclusions containing TAR DNA binding protein 43 (TDP-43) are a pathological hallmark of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). One of the disease-specific features of TDP-43 inclusions is the aberrant phosphorylation of TDP-43 at serines 409/410 (pS409/410). Here, we developed rabbit monoclonal antibodies (mAbs) that specifically detect pS409/410-TDP-43 in multiple model systems and FTD/ALS patient samples. Specifically, we identified three mAbs (26H10, 2E9 and 23A1) from spleen B cell clones that exhibit high specificity and sensitivity to pS409/410-TDP-43 peptides in an ELISA assay...
2024: PloS One
keyword
keyword
309
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.